ARTHQ (Arch Therapeutics) Ending Cash Position: $0.03 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Ending Cash Position?

Arch Therapeutics ARTHQ -99.00% 12 Ending Cash Position is $0.03 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Arch Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2024 was $0.03 Mil.

Arch Therapeutics's quarterly Ending Cash Position declined from Dec. 2023 ($0.21 Mil) to Mar. 2024 ($0.03 Mil) but then increased from Mar. 2024 ($0.03 Mil) to Jun. 2024 ($0.03 Mil).

Arch Therapeutics's annual Ending Cash Position declined from Sep. 2021 ($2.27 Mil) to Sep. 2022 ($0.75 Mil) and declined from Sep. 2022 ($0.75 Mil) to Sep. 2023 ($0.22 Mil).

Arch Therapeutics Ending Cash Position Related Terms

Arch Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Ending Cash Position Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 0.96 2.27 0.75 0.22

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.22 0.21 0.03 0.03
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Arch Therapeutics's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.747+-0.524
=0.22

Arch Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.027+0.003
=0.03

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.03 Mil mean?
Arch Therapeutics (ARTHQ) has a Ending Cash Position of $0.03 Mil as of Jun. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Ending Cash Position too high?
Arch Therapeutics' current Ending Cash Position is $0.03 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Ending Cash Position compare to GRTSQ and MTEM?
Arch Therapeutics' Ending Cash Position of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current Ending Cash Position is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Ending Cash Position of $0.03 Mil. The current Ending Cash Position is $0.03 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Ending Cash Position is $0.03 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price